dc.contributor.author | Dumlu, Rıdvan | |
dc.contributor.author | Yurttutan Uyar, Neval | |
dc.contributor.author | Ayaş, Meltem | |
dc.contributor.author | Aksoy, Nilay | |
dc.contributor.author | Öztürk, Nur | |
dc.contributor.author | Sesin Kocagöz, Ayşe | |
dc.date.accessioned | 2023-01-10T08:14:29Z | |
dc.date.available | 2023-01-10T08:14:29Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Dumlu, R., Yurttutan Uyar, N., Ayaş, M., Aksoy, N., Öztürk, N. ve Sesin Kocagöz, A. (2022). Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria. Turkish Journal of Medical Sciences, 52(6), 1839-1844. https://dx.doi.org/10.55730/1300-0144.5530 | en_US |
dc.identifier.issn | 1300-0144 | |
dc.identifier.issn | 1303-6165 | |
dc.identifier.uri | https://dx.doi.org/10.55730/1300-0144.5530 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/10275 | |
dc.description.abstract | Background/aim: Our study investigated the susceptibility rate of ceftazidime-avibactam and the risk factors associated with its resistance by analyzing gram-negative bacteria isolated from various patient samples. Materials and methods: Between March and November 2020, 1119 gram-negative bacteria strains were isolated from patient samples in Acıbadem Healthcare Group hospitals; ceftazidime-avibactam susceptibility results were evaluated using a 10/4µg (Oxoid, UK) disc and evaluated according to Eucast 2020 recommendations. Patient and isolate characteristics that could be risk factors were retrospectively investigated and statistically analyzed using SPSS 25.0. Results: Male patients made up 52% (n = 581) of the study’s total patient population, and they averaged 55.5 ± 24.9 years old. Of 1119 gram-negative strains culture and antibiogram, 1023 (91.4%) were sensitive to ceftazidime-avibactam. An increased risk of resistance was observed with female gender (OR = 2.29; CI 95% [1.45–3.61]; p < 0.05), Pseudomonas aeruginosa (OR = 1.67, CI 95% [1.03–2.7]; p < 0.05), the presence of multidrug-resistance (MDR) (OR = 4.07, CI 95% [2.47–6.7]; p < 0.05) pandrug-resistance (PDR) (OR = 12, (CI) 95% [9.9–14.7] ]; p < 0.05) and admission to intensive care unit (ICU) (OR = 1.89, CI 95% [1.22–2.93]; p < 0.05). Conclusion: The resistance rate of ceftazidime-avibactam was found to be 8.6%, and it was thought that resistant strains produced metallo-ß-lactamase (MBL) type carbapenemase. Risk factors were female gender, Pseudomonas aeruginosa, MDR, PDR, and admission to ICU. Therefore, studying the ceftazidime-avibactam susceptibility test together with gram-negative bacteria identification, especially in groups at risk for resistance, is one of the important factors that can positively affect the success of treatment. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Turkiye Klinikleri | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Antimicrobial Agents | en_US |
dc.subject | Drug-Resistant | en_US |
dc.subject | Multidrug-Resistant | en_US |
dc.subject | Ceftazidime-Avibactam Combination | en_US |
dc.subject | Gram-Negative Bacteria | en_US |
dc.title | Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Turkish Journal of Medical Sciences | en_US |
dc.department | İstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Klinik Eczacılık Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-0356-3744 | en_US |
dc.identifier.volume | 52 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.startpage | 1839 | en_US |
dc.identifier.endpage | 1844 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.55730/1300-0144.5530 | en_US |
dc.institutionauthor | Öztürk, Nur | |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.wos | 000906716200012 | en_US |
dc.identifier.scopus | 2-s2.0-85144503666 | en_US |
dc.identifier.trdizinid | 1145646 | en_US |
dc.identifier.pmid | 36945980 | en_US |
dc.identifier.scopusquality | Q3 | en_US |